Nang Kuang Pharmaceutical Co., Ltd. (1752.TW)
TWD 41.8
(2.45%)
TWD 41.8
(2.45%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 605.96 Million TWD | 47.98% |
| 2022 | 409.49 Million TWD | -23.25% |
| 2021 | 533.54 Million TWD | 23.65% |
| 2020 | 431.49 Million TWD | -9.7% |
| 2019 | 477.84 Million TWD | 0.35% |
| 2018 | 476.19 Million TWD | -39.56% |
| 2017 | 787.9 Million TWD | 3.63% |
| 2016 | 760.31 Million TWD | 0.54% |
| 2015 | 756.22 Million TWD | -28.71% |
| 2014 | 1.06 Billion TWD | 7.02% |
| 2013 | 991.17 Million TWD | -9.56% |
| 2012 | 1.09 Billion TWD | 44.67% |
| 2011 | 757.59 Million TWD | -7.17% |
| 2010 | 816.09 Million TWD | 12.23% |
| 2009 | 727.15 Million TWD | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q1 | 295.42 Million TWD | -51.25% |
| 2024 Q2 | 528.95 Million TWD | 79.05% |
| 2023 Q4 | 605.96 Million TWD | 0.46% |
| 2023 Q1 | 403.3 Million TWD | -1.51% |
| 2023 FY | 605.96 Million TWD | 47.98% |
| 2023 Q2 | 454.94 Million TWD | 12.81% |
| 2023 Q3 | 603.21 Million TWD | 32.59% |
| 2022 Q3 | 485.96 Million TWD | -0.1% |
| 2022 FY | 409.49 Million TWD | -23.25% |
| 2022 Q4 | 409.49 Million TWD | -15.73% |
| 2022 Q2 | 486.43 Million TWD | -5.18% |
| 2022 Q1 | 512.98 Million TWD | -3.85% |
| 2021 Q2 | 451.91 Million TWD | 3.56% |
| 2021 Q3 | 539.57 Million TWD | 19.4% |
| 2021 FY | 533.54 Million TWD | 23.65% |
| 2021 Q4 | 533.54 Million TWD | -1.12% |
| 2021 Q1 | 436.36 Million TWD | 1.13% |
| 2020 Q4 | 431.49 Million TWD | -9.66% |
| 2020 Q2 | 512.58 Million TWD | -5.68% |
| 2020 FY | 431.49 Million TWD | -9.7% |
| 2020 Q3 | 477.66 Million TWD | -6.81% |
| 2020 Q1 | 543.48 Million TWD | 13.74% |
| 2019 Q1 | 411.89 Million TWD | -13.5% |
| 2019 Q4 | 477.84 Million TWD | 6.71% |
| 2019 FY | 477.84 Million TWD | 0.35% |
| 2019 Q3 | 447.79 Million TWD | 32.27% |
| 2019 Q2 | 338.55 Million TWD | -17.81% |
| 2018 Q2 | 531.46 Million TWD | -16.83% |
| 2018 Q3 | 588.95 Million TWD | 10.82% |
| 2018 FY | 476.19 Million TWD | -39.56% |
| 2018 Q1 | 638.99 Million TWD | -18.9% |
| 2018 Q4 | 476.19 Million TWD | -19.15% |
| 2017 Q3 | 810.92 Million TWD | 13.48% |
| 2017 Q4 | 787.9 Million TWD | -2.84% |
| 2017 FY | 787.9 Million TWD | 3.63% |
| 2017 Q1 | 726.85 Million TWD | -4.4% |
| 2017 Q2 | 714.56 Million TWD | -1.69% |
| 2016 Q4 | 760.31 Million TWD | -1.26% |
| 2016 FY | 760.31 Million TWD | 0.54% |
| 2016 Q3 | 769.99 Million TWD | 16.67% |
| 2016 Q2 | 659.97 Million TWD | -11.28% |
| 2016 Q1 | 743.89 Million TWD | -1.63% |
| 2015 Q3 | 892.65 Million TWD | -22.69% |
| 2015 Q4 | 756.22 Million TWD | -15.28% |
| 2015 FY | 756.22 Million TWD | -28.71% |
| 2015 Q1 | 1.11 Billion TWD | 5.37% |
| 2015 Q2 | 1.15 Billion TWD | 3.29% |
| 2014 Q2 | 952.81 Million TWD | -2.15% |
| 2014 Q1 | 973.7 Million TWD | -1.76% |
| 2014 Q4 | 1.06 Billion TWD | 9.29% |
| 2014 Q3 | 970.58 Million TWD | 1.86% |
| 2014 FY | 1.06 Billion TWD | 7.02% |
| 2013 Q4 | 991.17 Million TWD | -2.83% |
| 2013 Q1 | 880.61 Million TWD | -19.65% |
| 2013 Q2 | 863.45 Million TWD | -1.95% |
| 2013 Q3 | 1.02 Billion TWD | 18.13% |
| 2013 FY | 991.17 Million TWD | -9.56% |
| 2012 FY | 1.09 Billion TWD | 44.67% |
| 2012 Q1 | 819.12 Million TWD | 8.12% |
| 2012 Q4 | 1.09 Billion TWD | 6.6% |
| 2012 Q3 | 1.02 Billion TWD | 0.72% |
| 2012 Q2 | 1.02 Billion TWD | 24.63% |
| 2011 Q3 | 947.51 Million TWD | 11.47% |
| 2011 FY | 757.59 Million TWD | -7.17% |
| 2011 Q1 | 881.27 Million TWD | 7.99% |
| 2011 Q2 | 850.03 Million TWD | -3.54% |
| 2011 Q4 | 757.59 Million TWD | -20.04% |
| 2010 Q4 | 816.09 Million TWD | 0.0% |
| 2010 FY | 816.09 Million TWD | 12.23% |
| 2009 FY | 727.15 Million TWD | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Maxigen Biotech Inc. | 50 Thousand TWD | -1211824.0% |
| SciVision Biotech Inc. | 347.91 Million TWD | -74.171% |
| Bionime Corporation | 2.81 Billion TWD | 78.491% |
| Pegavision Corporation | 1.56 Billion TWD | 61.256% |
| Visco Vision Inc. | 1.08 Billion TWD | 44.088% |